Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV.
about
The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trialsPhysiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model VerificationAccelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies.Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophagesDrug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment.Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation.Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy.In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents.Simulating Intestinal Transporter and Enzyme Activity in a Physiologically Based Pharmacokinetic Model for Tenofovir Disoproxil Fumarate.Long acting systemic HIV pre-exposure prophylaxis: an examination of the field.Validation of Computational Approaches for Antiretroviral Dose OptimizationPhysiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug-drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART.Physiologically based pharmacokinetic modeling of nanoceria systemic distribution in rats suggests dose- and route-dependent biokinetics.
P2860
Q28087336-1F61C3CE-3F72-4241-8D13-0BAC49F7691DQ28088352-7DB8871B-5D70-4D15-BDCE-76FEB9AFA3BDQ28821119-8DE335D3-AA7C-4616-8A0F-50EA9DA2FE84Q35016131-1A4EDA1B-A7DB-4E81-A199-3AA454DD0129Q36934918-C51510B3-A2B1-436F-ABA4-58435E249629Q37538717-BECBD2DF-21B3-4268-A7E5-03F261872648Q38750666-7E96EED7-8786-4CAC-A36B-BD8C9181564BQ38765921-52DE9AB3-7B48-4D14-82B2-D3776AAF7B9DQ38833637-E8D6B198-0DD9-4627-9C24-56ADB9626C3CQ39371494-F137B5B2-0CEE-413D-95D8-A8F47C0DF136Q39863986-00E4338B-A10E-4B4A-9461-6CDFDDA320D4Q48524975-F1A5969B-05A6-40ED-9855-D190F1826803Q53683300-04643848-D264-4A14-9E21-34F06D2325C4
P2860
Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Physiologically Based Pharmaco ...... ting Nanoformulations for HIV.
@ast
Physiologically Based Pharmaco ...... ting Nanoformulations for HIV.
@en
type
label
Physiologically Based Pharmaco ...... ting Nanoformulations for HIV.
@ast
Physiologically Based Pharmaco ...... ting Nanoformulations for HIV.
@en
prefLabel
Physiologically Based Pharmaco ...... ting Nanoformulations for HIV.
@ast
Physiologically Based Pharmaco ...... ting Nanoformulations for HIV.
@en
P2860
P50
P1476
Physiologically Based Pharmaco ...... cting Nanoformulations for HIV
@en
P2093
Charles Flexner
David J Back
P2860
P2888
P304
P356
10.1007/S40262-014-0227-1
P577
2015-06-01T00:00:00Z